news
Biodegradable gel boosts immune system’s attack on several cancers in mice
A new biodegradable gel can release drugs and special antibodies that simultaneously deplete macrophages from the surgical site and activate T cells.
List view / Grid view
Immuno-oncology
news
Simple delivery method that enhances a promising cancer treatment
Scientists have developed a delivery method that enhances treatment by adding CAR T cells and specialising signalling proteins to a hydrogel that is injected next to a tumour.
article
Viewing disease through the lens of memory B cells: improving cancer and infectious disease treatment
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
article
Triggering ferroptosis in cancer cells
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.
article
Drug Target Review Antibodies ebook 2022
This ebook includes articles about antibody-based therapies that could protect against cancer by utilising a patient's memory B cells. Also included is a piece on an intranasally-delivered monoclonal antibody treatment to potentially protect against SARS-CoV-2.
article
Drug Target Review Immuno-oncology ebook 2022
Included in this ebook are articles on how to develop more effective CAR T cells by modifying the CAR design and why recent findings about ferroptosis in cancer cells could enhance immunotherapies.
article
Uniting industry and academia for phenotypic drug discovery
A collaboration between Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) has been established to source cellular functional assays from the global academic community, with the goal of developing novel screens and identifying targets and therapeutic candidates for unmet medical needs. Here, Dr Denise Barrault, Director of…
news
Novel genome-wide approach to engineer more effective immunotherapy
Scientists have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumour cells.
news
Team creates new nanoplatform for delivering drugs into T cells
Researchers have developed a pH-sensitive drug delivery system in T cells using C-terminal dendrimers with Phenylalanine.
news
Research reveals CDH17 represents a new approach to treat solid cancers
Pre-clinical research has found that CAR T cells can suppress gastrointestinal cancer cells without causing harm to healthy tissues.
news
CAR T-cell implant effective at attacking cancer in pre-clinical study
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
news
New potential therapy developed in response to bladder cancer
Research in mice has shown that adding anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumour growth.
article
Drug Target Review – Issue 1 2022
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
news
Promising potential therapeutic strategy against pancreatic cancer developed
Scientists have discovered a new strategy that can make pancreatic tumours visible to the immune systems of mice and vulnerable to immune attack.
news
Pre-clinical study shows significant increase in effectiveness of breast cancer immunotherapy
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
